These results suggested that treatment with a combination of lorlatinib and erlotinib might be more effective at intervention in the initial phase than at the lorlatinib-acquired resistance phase during the growth of ALK-rearranged NSCLC cells. The gene discussed is ALK; the disease is non-small cell lung carcinoma.